In this issue:
Telaprevir + PEG-IFN-α2a/RBV in HCV/HIV-1
Sofosbuvir: 12 weeks effective in HCV GT-1, 4, 5 or 6 and in HCV GT-2 or 3 and for previously untreated chronic HCV
HCV reinfection common among prisoners
Boceprevir + PEG-IFN/RBV: an option for HCV/HIV?
Boceprevir-based regimens cost-effective in HCV
HCC risk endures after HCV eradication
Delayed vs immediate treatment in acute HCV
Please login below to download this issue (PDF)